Evogene gets 180-day Nasdaq bid-price extension
The notice leaves Nasdaq trading in place during the cure period, but continued listing depends on meeting the stated bid-price test.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evogene Ltd. (EVGN) received a Nasdaq letter granting an additional 180 calendar days, through March 29, 2027, to regain compliance with the minimum bid-price requirement. Compliance requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the period.
The letter has no immediate effect on Evogene’s Nasdaq listing or trading. If Evogene does not demonstrate compliance with the bid-price or other listing requirements by March 29, 2027, Nasdaq staff will provide written notification that its securities will be delisted. If the issue remains unresolved, Evogene intends to consider other options, potentially including a reverse share split.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Delisting notice possible if requirements remain unmet by March 29, 2027.
Filing Explained
The Nasdaq cure period does not extend to Evogene’s other exchange: the company says the letter has no bearing on its Tel Aviv Stock Exchange listing, which remains unaffected by this Nasdaq bid-price deficiency.
Key Figures
Key Terms
minimum bid price requirement regulatory
closing bid price market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much time does EVGN have to regain Nasdaq bid-price compliance?
What bid price does EVGN need to meet Nasdaq’s requirement?
Does Nasdaq’s notice immediately affect EVGN trading?
Does Nasdaq’s notice affect Evogene’s TASE listing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On September 30, 2026 Evogene Ltd., or Evogene, issued a press release announcing the receipt of a letter from the Nasdaq Stock Market LLC, regarding the grant of additional 180-day period, through March 29, 2027, to regain minimum bid price compliance. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (SEC File No. 333-277565 and 333-294650) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 30, 2026 |
EVOGENE LTD. (Registrant) By: /s/ Ofer Haviv —————————————— Ofer Haviv Chief Executive Officer |
EXHIBIT INDEX
| EXHIBIT NO. | DESCRIPTION |
| 99.1 | Press Release: Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance |
Exhibit 99.1
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Rehovot, Israel – September 30, 2026 – Evogene Ltd. (Nasdaq, TASE: EVGN) (the “Company”, “Evogene”), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”), indicating that on March 30, 2026 the Company was notified, based on the previous 30 consecutive business days, that it is not in compliance with Nasdaq Rule 5550(a)(2), as the Company’s closing bid price for its ordinary shares has been below $1.00 per share. Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until September 28, 2026, to regain compliance.
According to the Letter, the Nasdaq staff determined that the Company is eligible for an additional 180 calendar day period, until March 29, 2027, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed.
If the Company does not demonstrate compliance (with the bid price requirement or with any other listing requirements) prior to the end of the 180-day period ending March 29, 2027, Nasdaq’s staff will provide written notification that the Company’s securities will be delisted.
It is noted that Evogene’s continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially affecting a reverse share split among other alternatives.
The Letter from Nasdaq has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company’s ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “EVGN”. It is further noted that the Letter from Nasdaq has no bearing on Evogene’s listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol “EVGN”.
About Evogene Ltd.:
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to future events. These statements may be identified by words such as “may,” “could,” “expects,” “hopes,” “intends,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” “demonstrates,” “designed to,” “intended to,” “with the goal of,” or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses its ability to regain compliance under Nasdaq’s Listing Qualification requirements including by potentially affecting a reverse share split to regain the $1.00 minimum bid compliance. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent wars between Israel and each of (i) the terrorist groups Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those additional risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their preclinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Investor Relations Contact:
ir@evogene.com
Tel: +972-8-9311901